GRIFOLS, S.A.

Founded in Barcelona in 1909, Grifols, S.A. is a global healthcare company that develops, manufactures and supplies plasma-derived medicines and other biopharmaceutical solutions for patients with chronic, rare and, at times, life-threatening conditions. It operates what it describes as the world's largest network of plasma donation centers and serves more than 110 countries, employing over 23,000 people across more than 30 countries and regions.

Technical work at Grifols spans plasma fractionation, plasma-derived medicines, biopharmaceuticals, transfusion medicine, clinical diagnostics and pharmaceutical manufacturing. The company's portfolio includes a transfusion medicine solutions range designed to enhance safety from donation to transfusion, diagnostic technologies used in clinical settings, and biological supplies for life-science research and pharmaceutical manufacturing. Its therapeutic reach covers areas including immunology, infectious diseases, pulmonology, critical care, hepatology, hematology and neurology.

Operations are distributed across North America, Europe, Africa, the Middle East and China, from collection and fractionation through to diagnostics and supply. The company describes itself as a pioneer in the plasma industry and states a mission of improving the health and well-being of people worldwide.